Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the stock extended ...

Eli Lilly recently spoke out against proposed tariffs on pharmaceuticals, warning they could increase drug costs and restrict patient access. The drugmaker said it has invested more than $50 billion ...

Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...

Indianapolis-based Eli Lilly and Co. has operated in Ireland since the late 1970s and has more than 3,500 employees there.

CNBC host Jim Cramer says that the stock of Eli Lilly (LLY) has been “laid to waste” after the pharmaceutical giant reported ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Morning. Today, we see march-in rights return to the headlines, ponder how Eli Lilly’s plan to hike list prices in Europe may ...